<DOC>
	<DOCNO>NCT01491841</DOCNO>
	<brief_summary>Part 1 : This phase I trial combination bendamustine , rituximab pixantrone patient relapsed/refractory B cell non-Hodgkin lymphoma . A standard 3+3 design use determine maximum tolerate dose ( MTD ) combination . A static dose bendamustine rituximab use dose pixantrone escalate cohort . Pixantrone dose 21 day cycle 55mg/m2 , 85mg/m2 , 115mg/m2 sequential cohort dependent acceptable toxicity profile dose level . MTD determine base DLTs occur first 2 cycle drug combination . After 2 cycle study drug , subject achieve stable disease well may continue study 6 cycle . However , adverse event occur cycle 3-6 consider DLTs contribute determination MTD . Part 2 : After MTD determine expansion study plan . This phase II , prospective , open label , single arm study combination therapy bendamustine , rituximab , pixantrone define MTD schedule base phase I portion study . Subjects enrol part 2 study must aggressive , relapsed refractory B-cell NHL , include follicular lymphoma ( FL ) grade 3 , Diffuse Large B Cell Lymphoma ( DLBCL ) , transform NHL , mantle cell lymphoma ( MCL ) , aggressive histology . We anticipate total sample size 36 patient accrue rate 2 patient per month . Restaging employed cycle 2 , patient stable disease well may continue study 6 cycle .</brief_summary>
	<brief_title>IIT CTI Bendamustine , Rituximab , Pixantrone Relapsed/Refractory B Cell Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>Part 1 : This phase I trial utilize traditional 3+3 design evaluate maximum tolerate dose ( MTD ) optimal dose schedule pixantrone combination bendamustine ( 120mg/m2 day 1 21 day cycle ) rituximab ( 375mg/m2 day 1 21 day cycle ) . No patient enter escalated dosage level least 3 patient treat previous level assess dose limiting toxicity . Dose level escalate cohort 3 patient long drug-related DLT occur first 2 cycle . If one patient observe suffer DLT , cohort expand include least 6 patient total . If less 2 patient expand cohort 6 patient experience DLT , dose escalation resume . If 2 6 patient enrol dose level experience DLT , MTD exceed , dose escalation cease . The next low dose consider MTD . If patient withdraws study prior complete 2 cycle reason DLT patient replace order determine MTD . If dose limit toxicity observe initial dose level 2 patient , MTD exceed start dose level reduce 25mg/m2 . If 1 patient experience DLT -1 dose range , cohort expand least 6 patient . If second patient experience DLT -1 dose level , trial close . For part 1 , confirm diagnosis relapsed/refractory B cell non-Hodgkin 's lymphoma subtype consider eligible enrollment . Each cycle 21 day . Subjects assess DLTs first 2 cycle study drug . They assess response cycle 2 . Patients experience DLT first 2 cycle stable disease well may continue receive 6 cycle treatment triplet combination . If patient withdraws study prior complete 2 cycle reason DLT patient replace order determine MTD . Part 2 : It phase II , prospective , open label , single arm study combination bendamustine , pixantrone rituximab . The dose pixantrone MTD determine Part 1 study . A confirmed diagnosis aggressive , relapsed refractory B cell NHL , include follicular lymphoma ( FL ) grade 3 , Diffuse Large B Cell Lymphoma ( DLBCL ) , transform NHL , mantle cell lymphoma ( MCL ) , B cell NHL aggressive histology ( per update 2008 WHO criterion ) require participate phase II portion study . Cycle length 21 day . Restaging employed cycle 2 , patient stable disease well , may continue study 6 cycle maximum restaging perform hematologic recovery follow final cycle therapy . Bendamustine 120mg/m2 IV day 1 . Rituximab 375mg/m2 IV day 1 . Pixantrone MTD determine Part 1 study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Pixantrone</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>1 . Part I : Subjects must relapse refractory B cell NHL ; 2 . Part II : Subjects must relapse refractory aggressive B cell NHL include follicular lymphoma ( FL ) grade 3 , Diffuse Large B Cell Lymphoma ( DLBCL ) , transform NHL , mantle cell lymphoma ( MCL ) , aggressive B cell NHL histology per WHO 2008 criterion ; 3 . Refractory disease ( define persistence evaluable disease therapy ) relapse disease follow least one prior treatment regimen include autologous stem cell transplant unless patient eligible refuse prior transplant ; 4 . Age ≥ 18 year old ; 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 ; 6 . Subjects must measurable evaluable disease base physical exam and/or radiograph ( CT , MRI , PET ) bone marrow involvement ; 7 . Female subject either postmenopausal surgically sterilize ; 8 . Laboratory Values : Absolute neutrophil count ( ANC ) ≥ 1.5 x 10^9/L ; low level accept due marrow involvement lymphoma Platelets ≥ 75,000/mcl ; low level accept due marrow involvement lymphoma Total bilirubin ≤ 1.5 X institutional upper limit normal ; ≤ 3.0 ULN accept subject Gilbert 's Syndrome AST/ALT ≤ 1.5 X institutional upper limit normal . Subjects know liver involvement lymphoma : AST/ALT ≤ 2 X institutional upper limit normal Serum creatinine &lt; 1.5 X institutional upper limit normal 9 . Ability provide write informed consent obtain prior participation study relate procedure perform 1 . No chemotherapy , radiation , biologics immunotherapy within 2 week prior registration ( 6 week last receive BCNU mitomycin C ) . 2 . No radioimmunotherapy within 2 month prior registration . 3 . Subjects receive chronic , systemic treatment corticosteroid equivalent &gt; 20mg prednisone per day . Subjects receive replacement adrenal insufficiency allow study . Topical inhale corticosteroid allow . 4 . Subjects history another primary malignancy ≤ 3 year ago , exception inactive basal , squamous cell carcinoma skin superficial melanoma require excision , prostate cancer PSA increase least 3 month , carcinoma situ cervix . 5 . Major surgery ≤ 4 week prior registration . Minor surgery ≤ 2 week prior registration . Insertion vascular access device consider major minor surgery . Subjects must recover surgery related toxicity ≤ grade 1 baseline subject start &gt; grade 1 toxicity , otherwise violate inclusion criterion . 6 . Subjects receive investigational drug ≤ 4 week prior registration . 7 . Impaired Cardiac Function : QTc &gt; 480 screening ECG . Previous history angina pectoris acute MI within 6 month Congestive heart failure ( New York Heart Association functional classification IIIIV ) baseline MUGA/ECHO show estimate LVEF &lt; 45 % Any history torsade de pointes , ventricular fibrillation , uncontrolled ventricular tachycardia , uncontrolled atrial fibrillation . 8 . Female patient pregnant breastfeed 9 . Patients history untreated hepatitis B know carrier hepatitis B exclude trial . All subject screen prior study entry . 10 . Concurrent use anticancer agent anticancer treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>